UNSPSC 51384209: Loxoprofen sodium dihydrate

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H17O3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z2DR42L11Y, chemically known as benzeneacetic acid, .alpha.-methyl-4-((2-oxocyclopentyl)methyl)-, sodium salt, hydrate (1:1:2), but more generally known as loxoprofen sodium dihydrate, which bears US NIH Compound Identifier 157322.

European Medicines Agency schedules loxoprofen sodium dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08609MIG. Most nations, for tariff purposes, schedule loxoprofen sodium dihydrate under HS 29183000. SMILES: CC(C1CCC(CC1)CC2CCCC2=O)C(=O)[O-].O.O.[NA+].

UNSPSC 51384209 Loxoprofen sodium dihydrate, a Commodity code, shows a significant mismatch between its nominal scope and actual state and local procurement activity. The code nominally refers to a specific nonsteroidal anti-inflammatory drug, but the recent opportunity tagged under it — Seminole County, Florida's IFB60459723LAS — solicits naloxone and drug deactivation systems for community health initiatives, products entirely unrelated to loxoprofen. This tagging misalignment suggests either a cataloging error in the source system or a deliberate but unexplained code assignment that does not reflect the drug's pharmaceutical category.

The single recent opportunity on record does not support a characterization of issuing-body mix, geographic concentration, or repeat-buyer patterns under this code. Seminole County's naloxone and drug-deactivation procurement (IFB posted June 30, 2026, due July 26, 2023) was structured as a competitive IFB with an initial two-year term and one-year renewal option, requiring quarterly deliveries and vendor compliance with drug-free workplace certification, E-Verify, workers' compensation, and commercial general liability insurance. No other state or local loxoprofen sodium dihydrate opportunities appear in the source, and the single naloxone record does not reflect the code's intended commodity scope. This code shows little relevant recent activity for business development purposes.